Press release
Malmö, Sept 3, 2018
Acarix Clinical Advisory Board meeting held in parallel to ESC-conference in Munich, Germany, confirms validity of its comprehensive clinical study program.
Acarix AB (publ) (“Acarix”), today reported positive feedback for the clinical study program in order to validate and expand the performance of theCADScor®System.
At the Advisory Board meeting in parallel to the ESC congress the company presented its clinical plan moving forward with additional performance and cost-benefit trials as well as new exploratory studies.
“The strength of the Acarix CADScor®System has been proven in a number of clinical studies and the overall findings support the concept of using CADScor®System as a frontline test for early rule-out of stable CAD (Coronary Artery Disease). Today’s presented clinical program even expands the basis for clinical evidence.” says Professor Dr. Christian Hamm from UKGM Giessen, Germany.
Acarix has recently reported the positive results of the DAN-Nicad study, a large-scale study in a relevant patient population showing the high sensitivity and negative predictive value of the CADScor®System as a first line test for CAD rule out.
“With our ambitious clinical study program Acarix strives to further strengthen the position as an effective, cost saving and game changing CAD rule-out device. It is therefore a great pleasure to get confirmation from our renowned advisors who have been supporting our clinical development for the last three years”, says Acarix COO Claus Bo Vöge Christensen.
Contacts:
Christian Lindholm, interim CEO, E-mail: secli@acarix.com, Phone: +46 705 118 333
Notes to editors:
Acarix, CADScor®System and cardiac sound measurement
Acarix was established in 2009 and is listed on Nasdaq First North Premier. Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. Readings are obtained in less than 8 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor®System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful invasive diagnostic procedures.
See more at www.acarix.com. Press photos: http://www.acarix.com/about-us/press-downloads/press-photos/.
—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire